According to a recent Reuters article, the FDA has asked three major drug companies to update safety restrictions for their arthritis drugs. The drugs in question belong to the class of treatments known as JAK inhibitors, which treat rheumatoid arthritis. All three drugs: Pfizer’s Xeljanz, AbbVie’s Rinvoq, and Eli Lilly’s Olumiant, currently have boxed warnings about blood clots and lymphoma. With updated warnings, the FDA is essentially pushing back the drugs’ place in the treatment sequence and limiting their use.
FDA Wants New Warnings for Arthritis Drugs
The agency is requiring Pfizer, Eli Lilly, and AbbVie to include new heart safety and cancer warnings on the drugs.
Sep 8, 2021
FDA warning letters surge - is your team prepared?
New guide reveals expert strategies to prevent regulatory issues and respond effectively to FDA enforcement actions in pharmaceutical and medical device manufacturing.
Read More
List: Digitalization Companies From PACK EXPO
Looking for CPG-focused digital transformation solutions? Download our editor-curated list from PACK EXPO featuring top companies offering warehouse management, ERP, digital twin, and MES software with supply chain visibility and analytics capabilities—all tailored specifically for CPG operations.
Download Now